Compile Data Set for Download or QSAR
Report error Found 18 Enz. Inhib. hit(s) with all data for entry = 3387
TargetTyrosine-protein kinase JAK1(Human)
Eli Lilly

US Patent
LigandPNGBDBM398506(US10323019, Example 10 | (2R)-1,1,1-Trifluoro-3-({...)
Affinity DataIC50: 1.49nMAssay Description:The JAK LanthaScreen Kinase Assay (Invitrogen) is used to determine the ability of test compounds to inhibit JAK1, JAK2, and JAK3 kinase activity. Th...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/10/2020
Entry Details
US Patent

TargetTyrosine-protein kinase JAK1(Human)
Eli Lilly

US Patent
LigandPNGBDBM398504(US10323019, Example 8 | (2R)-1,1,1-Trifluoro-3-[(c...)
Affinity DataIC50: 1.91nMAssay Description:The JAK LanthaScreen Kinase Assay (Invitrogen) is used to determine the ability of test compounds to inhibit JAK1, JAK2, and JAK3 kinase activity. Th...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/10/2020
Entry Details
US Patent

TargetTyrosine-protein kinase JAK1(Human)
Eli Lilly

US Patent
LigandPNGBDBM398501(US10323019, Example 1 | (2R)-1,1,1-Trifluoro-3-({c...)
Affinity DataIC50: 3.25nMAssay Description:The JAK LanthaScreen Kinase Assay (Invitrogen) is used to determine the ability of test compounds to inhibit JAK1, JAK2, and JAK3 kinase activity. Th...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/10/2020
Entry Details
US Patent

TargetTyrosine-protein kinase JAK1(Human)
Eli Lilly

US Patent
LigandPNGBDBM398502(US10323019, Example 6 | (2R)-1,1,1-Trifluoro-3-{[c...)
Affinity DataIC50: 5.25nMAssay Description:The JAK LanthaScreen Kinase Assay (Invitrogen) is used to determine the ability of test compounds to inhibit JAK1, JAK2, and JAK3 kinase activity. Th...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/10/2020
Entry Details
US Patent

TargetTyrosine-protein kinase JAK1(Human)
Eli Lilly

US Patent
LigandPNGBDBM398505(US10323019, Example 9 | (2R)-3-{[cis-4-({4-[(1,5-D...)
Affinity DataIC50: 5.35nMAssay Description:The JAK LanthaScreen Kinase Assay (Invitrogen) is used to determine the ability of test compounds to inhibit JAK1, JAK2, and JAK3 kinase activity. Th...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/10/2020
Entry Details
US Patent

TargetTyrosine-protein kinase JAK1(Human)
Eli Lilly

US Patent
LigandPNGBDBM398503(US10323019, Example 7 | (2R)-3-{[(cis-4-({4-[(Ethy...)
Affinity DataIC50: 5.43nMAssay Description:The JAK LanthaScreen Kinase Assay (Invitrogen) is used to determine the ability of test compounds to inhibit JAK1, JAK2, and JAK3 kinase activity. Th...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/10/2020
Entry Details
US Patent

TargetTyrosine-protein kinase JAK2(Human)
Eli Lilly

US Patent
LigandPNGBDBM398506(US10323019, Example 10 | (2R)-1,1,1-Trifluoro-3-({...)
Affinity DataIC50: 220nMAssay Description:The JAK LanthaScreen Kinase Assay (Invitrogen) is used to determine the ability of test compounds to inhibit JAK1, JAK2, and JAK3 kinase activity. Th...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/10/2020
Entry Details
US Patent

TargetTyrosine-protein kinase JAK2(Human)
Eli Lilly

US Patent
LigandPNGBDBM398504(US10323019, Example 8 | (2R)-1,1,1-Trifluoro-3-[(c...)
Affinity DataIC50: 239nMAssay Description:The JAK LanthaScreen Kinase Assay (Invitrogen) is used to determine the ability of test compounds to inhibit JAK1, JAK2, and JAK3 kinase activity. Th...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/10/2020
Entry Details
US Patent

TargetTyrosine-protein kinase JAK3(Human)
Eli Lilly

US Patent
LigandPNGBDBM398506(US10323019, Example 10 | (2R)-1,1,1-Trifluoro-3-({...)
Affinity DataIC50: 660nMAssay Description:The JAK LanthaScreen Kinase Assay (Invitrogen) is used to determine the ability of test compounds to inhibit JAK1, JAK2, and JAK3 kinase activity. Th...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/10/2020
Entry Details
US Patent

TargetTyrosine-protein kinase JAK2(Human)
Eli Lilly

US Patent
LigandPNGBDBM398505(US10323019, Example 9 | (2R)-3-{[cis-4-({4-[(1,5-D...)
Affinity DataIC50: 767nMAssay Description:The JAK LanthaScreen Kinase Assay (Invitrogen) is used to determine the ability of test compounds to inhibit JAK1, JAK2, and JAK3 kinase activity. Th...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/10/2020
Entry Details
US Patent

TargetTyrosine-protein kinase JAK2(Human)
Eli Lilly

US Patent
LigandPNGBDBM398502(US10323019, Example 6 | (2R)-1,1,1-Trifluoro-3-{[c...)
Affinity DataIC50: 768nMAssay Description:The JAK LanthaScreen Kinase Assay (Invitrogen) is used to determine the ability of test compounds to inhibit JAK1, JAK2, and JAK3 kinase activity. Th...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/10/2020
Entry Details
US Patent

TargetTyrosine-protein kinase JAK2(Human)
Eli Lilly

US Patent
LigandPNGBDBM398503(US10323019, Example 7 | (2R)-3-{[(cis-4-({4-[(Ethy...)
Affinity DataIC50: 901nMAssay Description:The JAK LanthaScreen Kinase Assay (Invitrogen) is used to determine the ability of test compounds to inhibit JAK1, JAK2, and JAK3 kinase activity. Th...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/10/2020
Entry Details
US Patent

TargetTyrosine-protein kinase JAK3(Human)
Eli Lilly

US Patent
LigandPNGBDBM398504(US10323019, Example 8 | (2R)-1,1,1-Trifluoro-3-[(c...)
Affinity DataIC50: 1.17E+3nMAssay Description:The JAK LanthaScreen Kinase Assay (Invitrogen) is used to determine the ability of test compounds to inhibit JAK1, JAK2, and JAK3 kinase activity. Th...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/10/2020
Entry Details
US Patent

TargetTyrosine-protein kinase JAK2(Human)
Eli Lilly

US Patent
LigandPNGBDBM398501(US10323019, Example 1 | (2R)-1,1,1-Trifluoro-3-({c...)
Affinity DataIC50: 1.20E+3nMAssay Description:The JAK LanthaScreen Kinase Assay (Invitrogen) is used to determine the ability of test compounds to inhibit JAK1, JAK2, and JAK3 kinase activity. Th...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/10/2020
Entry Details
US Patent

TargetTyrosine-protein kinase JAK3(Human)
Eli Lilly

US Patent
LigandPNGBDBM398505(US10323019, Example 9 | (2R)-3-{[cis-4-({4-[(1,5-D...)
Affinity DataIC50: 2.14E+3nMAssay Description:The JAK LanthaScreen Kinase Assay (Invitrogen) is used to determine the ability of test compounds to inhibit JAK1, JAK2, and JAK3 kinase activity. Th...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/10/2020
Entry Details
US Patent

TargetTyrosine-protein kinase JAK3(Human)
Eli Lilly

US Patent
LigandPNGBDBM398502(US10323019, Example 6 | (2R)-1,1,1-Trifluoro-3-{[c...)
Affinity DataIC50: 2.54E+3nMAssay Description:The JAK LanthaScreen Kinase Assay (Invitrogen) is used to determine the ability of test compounds to inhibit JAK1, JAK2, and JAK3 kinase activity. Th...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/10/2020
Entry Details
US Patent

TargetTyrosine-protein kinase JAK3(Human)
Eli Lilly

US Patent
LigandPNGBDBM398501(US10323019, Example 1 | (2R)-1,1,1-Trifluoro-3-({c...)
Affinity DataIC50: 3.72E+3nMAssay Description:The JAK LanthaScreen Kinase Assay (Invitrogen) is used to determine the ability of test compounds to inhibit JAK1, JAK2, and JAK3 kinase activity. Th...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/10/2020
Entry Details
US Patent

TargetTyrosine-protein kinase JAK3(Human)
Eli Lilly

US Patent
LigandPNGBDBM398503(US10323019, Example 7 | (2R)-3-{[(cis-4-({4-[(Ethy...)
Affinity DataIC50: 6.16E+3nMAssay Description:The JAK LanthaScreen Kinase Assay (Invitrogen) is used to determine the ability of test compounds to inhibit JAK1, JAK2, and JAK3 kinase activity. Th...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/10/2020
Entry Details
US Patent